Phase III Comparative Clinical Trial of Treatment Schedules for Oral UFT/LV Therapy as Postoperative Adjuvant Chemotherapy for Stage IIB/III Colorectal Cancer
- Conditions
- colorectal cancer
- Registration Number
- JPRN-C000000245
- Lead Sponsor
- Japanese Foundation for Multidisciplinary Treatment of Cancer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 840
1) Histologically confirmed colorectal cancer
2) Histological Stage IIB, IIIA, IIIB, IIIC located in colon and rectosigmoid
3) Curative resection with D2 or more lymph node dissection
4) Resection of histological curability A was performed
5) Performance status (ECOG) 0, 1
6) No prior chemotherapy and radiotherapy
7) Oral intake is possible
8) Sufficient organ functions
a) WBC >= 3,000/mm3, <12,000/mm3
b) Neutrophil >=1,500/mm3
c) Hemoglobin >= 9.0g/dL
d) Platelet >= 100,000/mm3
e) Total bilirubin < 1.5mg/dL
f) AST, ALT < 100IU/L
g) Serum creatinine < 1.5mg/dL
9) Chemotherapy will be started within 6 weeks from operation
10) Written informed consent
1) active synchronous or metachronous malignancy other than carcinoma in situ
2) serious coexisting illness
a; severe pulmonary dysfunction
b; ileus or colon dysfunction
c; uncontrolled diabetes mellitus
d; liver cirrhosis
e; uncontrolled hypertension
f; history of myocardial infarction, unstable angina within 6 months prior to the registration
3) pregnant or nursing
4) severe mental disorders
5) not suitable for participating in the study for any other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method disease-free survival
- Secondary Outcome Measures
Name Time Method overall survival, incidence of adverse events